# LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 YTD Q2 P&L / Income Statement

- Company: LIGAND PHARMACEUTICALS INCORPORATED (LGND)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-07, accession number 0000886163-26-000044
- Page: https://plicit.ai/financials/lgnd/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/lgnd-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (14 categories)

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (14 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues and income**: 115,415,000 US dollars
- **Cost of revenue (calculated)**: 22,681,000 US dollars
- **Gross profit (calculated)**: 92,734,000 US dollars
- **Operating expenses (calculated)**: 66,775,000 US dollars
- **Operating income (loss)**: 25,959,000 US dollars
- **Total non-operating income (expenses), net**: 14,086,000 US dollars
- **Income (loss) before income taxes**: 40,045,000 US dollars
- **Income tax (expense) benefit**: 4,882,000 US dollars
- **Net income (loss)**: 35,163,000 US dollars
- **Contract revenue**: 2,793,000 US dollars
- **Income**: 5,000,000 US dollars
- **Qarziba**: 12,449,000 US dollars
- **Ohtuvayre inventors**: 6,341,000 US dollars
- **Other**: 1,907,000 US dollars
- **Filspari**: 24,889,000 US dollars
- **Kyprolis**: 13,784,000 US dollars
- **Ohtuvayre**: 7,131,000 US dollars
- **Rylaze**: 6,422,000 US dollars
- **Capvaxive**: 4,285,000 US dollars
- **Vaxneuvance**: 2,961,000 US dollars
- **Teriparatide injection**: 2,791,000 US dollars
- **Other**: 8,030,000 US dollars
- **Captisol**: 16,632,000 US dollars
- **Cost of Captisol**: 6,487,000 US dollars
- **Amortization of intangibles**: 16,194,000 US dollars
- **Research and development**: 16,816,000 US dollars
- **General and administrative**: 49,959,000 US dollars
- **Fair value adjustments to partner program derivatives**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (4 categories)

- Page: https://plicit.ai/financials/lgnd/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-4-categories
- Chart image: https://plicit.ai/charts/lgnd-fy2026-ytd-q2-revenue-by-product-and-service-4-categories-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (4 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues and income**: 115,415,000 US dollars
- **Cost of revenue (calculated)**: 22,681,000 US dollars
- **Gross profit (calculated)**: 92,734,000 US dollars
- **Operating expenses (calculated)**: 66,775,000 US dollars
- **Operating income (loss)**: 25,959,000 US dollars
- **Total non-operating income (expenses), net**: 14,086,000 US dollars
- **Income (loss) before income taxes**: 40,045,000 US dollars
- **Income tax (expense) benefit**: 4,882,000 US dollars
- **Net income (loss)**: 35,163,000 US dollars
- **Captisol**: 16,632,000 US dollars
- **Contract revenue and income**: 7,793,000 US dollars
- **Revenue from intangible royalty assets**: 70,293,000 US dollars
- **Income from financial royalty assets**: 20,697,000 US dollars
- **Cost of Captisol**: 6,487,000 US dollars
- **Amortization of intangibles**: 16,194,000 US dollars
- **Research and development**: 16,816,000 US dollars
- **General and administrative**: 49,959,000 US dollars
- **Fair value adjustments to partner program derivatives**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.